Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 16Gastrointestinal 11Other hematologic neoplasm 10Lymphoid 9Thoracic 8Sarcoma 7Plasma cell 7CNS 7Gynecologic 5Genitourinary 5Dermatologic 5Classical hematology 3Myeloid 2Other neoplasm 1Other 1

Conditions

Precancerous Conditions 138Lymphoma 35Leukemia 34Multiple Myeloma 33Leukemia, Lymphocytic, Chronic, B-Cell 32Neoplasms, Plasma Cell 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Monoclonal Gammopathy of Undetermined Significance 29Lymphoma, Non-Hodgkin 29Lymphoma, Mantle-Cell 29Lymphoma, Large-Cell, Immunoblastic 29Lymphoma, Large B-Cell, Diffuse 29Lymphoma, Follicular 29Burkitt Lymphoma 28Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 27Lymphoma, B-Cell, Marginal Zone 27Hodgkin Disease 27Myelodysplastic Syndromes 26Immunoglobulin Light-chain Amyloidosis 26Myeloproliferative Disorders 25Lymphoma, T-Cell, Cutaneous 25Immunoblastic Lymphadenopathy 25Waldenstrom Macroglobulinemia 24Lymphoma, Large-Cell, Anaplastic 24Leukemia, Myeloid, Acute 24Uterine Cervical Neoplasms 22Primary Myelofibrosis 22Leukemia, Large Granular Lymphocytic 22Leukemia, Hairy Cell 22Thrombocythemia, Essential 21

Interventions

Epoetin Alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Drug-Related Side Effects and Adverse Reactions × Other neoplasm × Clear all
NCT00003600 2016-07-13

Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy

Alliance for Clinical Trials in Oncology

Phase 3 Completed
344 enrolled
BreastClassical hematologyLymphoidMyeloidOther hematologic neoplasmOther neoplasmPlasma cellThoracic

Anemia, Breast Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Precancerous Conditions, Neoplasms, Plasma Cell, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡